COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Solutions Reports Pending Patent Grants in Europe and Eurasia, Strengthening IP Protection for Proprietary Sublingual Cladribine-Based MS Treatment
BioNxt Solutions Inc. makes significant progress in global patent portfolio with EPO and EAPO confirming acceptance of core claims for sublingual Cladribine thin-film formulation. Focus on innovation in MS treatment -
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Solutions Announces Closing of First Tranche of Convertible Debenture Unit Private Placement
BioNxt Solutions Inc. closes first tranche of non-brokered private placement, raising $1,009,200 for drug delivery tech and IP development. Securities subject to statutory hold until Nov 26, 2025 -
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Delivers Positive Results in Patented Cladribine Sublingual Thin-Film Program and Completes Successful Formulation
BioNxt Solutions Inc. announces successful development of sublingual thin-film prototype for cladribine-based drug delivery in multiple sclerosis treatment, strengthening clinical development path
